1 Min Read
March 28 (Reuters) - Idera Pharmaceuticals Inc said its experimental drug for an inflammatory skin disease was found safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial.
The company's shares rose about 40 percent to $5.40 in premarket trading on Friday.
Idera said there were no treatment-related discontinuations or severe adverse events reported in the 32 patients with moderate-to-severe plaque psoriasis enrolled in the study. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)